Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026914 | 0.98 | KDM4E (0.38) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 | |
| SCHEMBL11693982 | 0.79 | TGFBR1 (0.33) | SMN1; SMN2HSD17B10 | |
| SCHEMBL4760788 | 0.78 | POLB (0.33) | KDM4EMAPK1HIF1ASMN1; SMN2HSD17B10 | |
| SCHEMBL27967318 | 0.78 | TSHR (0.41) | MAPK1TSHR | |
| SCHEMBL6770533 | 0.76 | TSHR (0.42) | MAPK1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL27967486 | 0.74 | TSHR (0.41) | MAPK1TSHR | |
| SCHEMBL27967487 | 0.74 | TSHR (0.41) | MAPK1TSHR | |
| SCHEMBL28035014 | 0.74 | TSHR (0.41) | MAPK1TSHR | |
| Ammonia Solution, Strong SCHEMBL27967314 | 0.74 | TSHR (0.41) | MAPK1TSHR | |
| SCHEMBL27998594 | 0.74 | TSHR (0.41) | MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4156795-B2 | — | — | 2008-09-24 | — | — | JP | claimed |
| JP-2002501040-A | — | — | 2002-01-15 | — | — | JP | claimed |
| US-6265437-B1 | ALCOHOLISM | LIPHA (FR) | 2001-07-24 | — | — | US | claimed |
| EP-1051393-A1 | NEW DERIVATIVES OF SULFONIC, PHOSPHONIC AND PHOSPHINIC AMINOALKANE ACIDS, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | LIPHA (FR) | 2000-11-15 | — | — | EP | claimed |
| WO-1999037606-A1 | NEW DERIVATIVES OF SULFONIC, PHOSPHONIC AND PHOSPHINIC AMINOALKANE ACIDS, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | LIPHA (FR) | 1999-07-29 | — | — | WO | claimed |
| EP-1056445-B1 | ORALLY ADMINISTRABLE IMMEDIATE-RELEASE AND PROLONGED-RELEASE GALENIC FORM COMPRISING AN ABSORPTION-PROMOTING AGENT AND USE OF THIS ABSORPTION-PROMOTING AGENT | MERCK PATENT GMBH (DE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1410791-A1 | Orally administrable galenic form comprising metformine and an absorption-promoting agent | MERCK PATENT GmbH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6514524-B1 | Improved absorption of hydrophilic ingredients because of particular excipients; calcium 3-acetylamino-1-propane sulfonate (calcium acamprosate); polysorbates, fatty ethers or esters of PEG, polyglycolysed glycerides | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-02-04 | — | — | US | disclosed |
| US-6426087-B1 | GALENIC FORMS; SUSTAINED RELEASE | MERCK PATENT GESELLSCHAFT MIT (DE) | 2002-07-30 | — | — | US | disclosed |
| US-6265437-B1 | ALCOHOLISM | LIPHA (FR) | 2001-07-24 | — | — | US | disclosed |